Moreover, we observed an increase in the mRNA and protein expression of TUFT1 in group A as compared with the control group and group B. However, we did not confirm that changes in the TUFT1 expression profile depend on the occurrence of drug resistance to platinum compounds in ovarian cancer. This evidence concerns the gene TUFT1 and ovarian cancer.